IQVIA, with its vast trove of health information, sits at the center of drug development, providing data, tools and services to conduct research and perform clinical trials. After a supply chain destocking cycle, growth and backlog are improving and have allowed the company to raise its guidance. IQVIA recently launched an AI platform in partnership with NVDIA. This could enhance its competitive advantage and accelerate drug development and demand. However, many investors aren't recognizing the potential value AI will unlock. Artificial intelligence is reshaping drug discovery, and IQVIA may be one of the market's most overlooked beneficiaries. The company owns a database of more than 1.2 billion healthcare records that function like a toll booth across the research and development process -- every new drug target, clinical trial, and AI-powered research initiative increases demand for its data and services. As drug companies race to develop medicines faster and more efficiently, IQVIA is positioned to benefit. Yet despite record backlog, growing AI adoption, rising market share, and improving earnings, the stock still trades near its lowest valuation in five years. Many investors feared that AI would allow healthcare and life sciences companies to bring research activities in-house, reducing demand for contract research providers like IQVIA. Instead, first-quarter results suggest the opposite: AI is helping customers identify more drug candidates, expand development pipelines, and increase demand for IQVIA's data, technology, and clinical research services. In the AI era, proprietary data is king, and few companies possess more valuable healthcare data than IQVIA. Its vast repository of patient records and clinical insights has become essential for modern drug development, creating a moat that competitors cannot easily replicate. As AI adoption accelerates, IQVIA's data assets should become even more valuable, strengthening its competitive position and supporting long-term growth. Why the stock weakness? The stock's discount reflects concerns that emerged following the post-Covid biotech downturn as clinical research demand weakened and biotech funding was constrained. This overhang began to lift in early 2026 as clinical research demand improved, bookings strengthened, and IQVIA raised its full-year earnings guidance following first-quarter results in May. Organic growth had accelerated across its business, with its commercial solutions revenue growth doubling and R & D solutions growth tripling year-over-year. However, the stock also has been pressured by skepticism over its AI investments and whether this spending would generate meaningful near-term revenue. Some also feared that IQVIA's clients could harness their own AI abilities to bring research in house, but that notion fails to appreciate the breadth of the information that IQVIA has. No single company can replicate it. It also runs counter to the industry's trend toward outsourcing. Unlike many AI initiatives that remain largely conceptual, IQVIA's AI offerings are already contributing to customer adoption, bookings activity, and management's improved outlook. AI: Friend or foe? Also, rather than displacing contract research organizations like IQVIA, AI is starting to help customers identify more drug targets and expand development pipelines, driving greater demand for IQVIA's data, technology, and research services. CEO Ari Bousbib highlighted this trend on the company's May earnings call, noting that AI is causing customers to ask more questions, not fewer. He cited one large pharmaceutical company that plans to double the number of molecules in its pipeline as AI uncovers new drug targets, creating additional demand for CRO services. The market is pricing IQVIA as if AI is a long-term threat to the clinical research model. The evidence increasingly suggests the opposite: AI is making IQVIA's proprietary data assets and embedded workflows more valuable, setting the stage for both earnings acceleration and multiple expansion. Although the shares have rebounded from roughly $160 to $180 since management raised guidance, they continue to trade well below historical valuation levels, leaving substantial room for multiple expansion as investors gain confidence in AI's impact on the business. Data creates competitive advantage IQVIA was created in 2016 through the merger of IMS Health, a pioneer in healthcare data analytics, and Quintiles, the world's largest CRO. The combination produced a unique asset: arguably one of the world's largest troves of healthcare records integrated with a leading clinical trial platform. Together, these capabilities make IQVIA an essential player in a highly complex and regulated industry. The company's data acts as a toll booth throughout the pharmaceutical ecosystem. Customers build critical research workflows around IQVIA's platform, resulting in retention rates exceeding 90% on core data contracts. The switching costs are substantial, as changing providers can disrupt research continuity, regulatory compliance, and clinical trial economics. As healthcare data becomes increasingly important to drug development, this competitive moat continues to widen. In March, the company launched IQVIA.ai, a life sciences-focused agentic AI platform developed in collaboration with Nvidia . The platform combines IQVIA's proprietary healthcare data and customer relationships with Nvidia's AI infrastructure to help pharmaceutical companies accelerate research, identify patients for clinical trials, and streamline administrative workflows. Already, 19 of the world's 20 largest pharmaceutical companies are using IQVIA.ai, while the company has filed more than 100 AI-related patents. Nvidia sees significant potential in the partnership. "Every moment counts when planning clinical trials, from discovery to commercial application," said Kimberly Powell, Nvidia's vice president of healthcare. "Working with industry leaders like IQVIA, we can build domain-specific agents that can demonstrate efficiency and precision." The timing could not be better. Drug development is becoming more complex, expensive, and data-intensive, particularly in areas such as oncology and precision medicine. At the same time, AI is enabling researchers to pursue more drug targets and design more efficient clinical trials. Both trends increase demand for high-quality healthcare data, strengthening IQVIA's position as an indispensable partner to the pharmaceutical industry. Undervalued market leader IQVIA commands about 43.6% of the market, according to financial media company CSIMarket. Evidence suggests it's gaining market share versus rivals such as Icon and Medpace , including IQVIA's growing backlog, which hit a record in the first quarter. Valuation Disconnect There is a stark disconnect between IQVIA's fundamental performance and its current market pricing. Shares plummeted in February after it lowered its original 2026 outlook, but the stock has not recovered following its raised guidance in May. At Tuesday's closing price of about $171, a two-stage discounted cash flow model — utilizing a 7% weighted average cost of capital and conservative growth deceleration — pegs IQVIA's true fair value at $326 per share, implying the market is pricing the equity at a 47% discount relative to its normalized future cash flows. Multiple re-rating potential If management continues to execute and AI-driven demand remains strong, IQVIA's current valuation appears difficult to justify. Improving growth, record backlog, rising cash generation, and ongoing deleveraging could support a return toward historical valuation ranges. Revenue at its newly streamlined commercial solutions segment surged 11.6% year-over-year driven by its high-margin, AI-enabled offerings gaining substantial enterprise traction, while its massive R & D Solutions contracted backlog climbed to a record $34.2 billion with an accelerating book-to-bill ratio. Furthermore, the $80 million interest expense headwind that depressed near-term earnings guidance following its 2025 financing activities has established a clear operational bottom. As IQVIA leverages its high-visibility, 99% free-cash-flow conversion to systematically pay down its $13.89 billion net debt pile and lower its 3.62x net leverage ratio, aggressive balance sheet deleveraging will drive multiple expansion back toward its historical forward P/E floor. IQVIA also is repurchasing stock. In the first quarter, it bought back $552 million of its shares. On May 7, the company increased its program by $2 billion to a total authorization of $3.2 billion. Expanding the buyback program signals management's strong confidence in the company's financial health, cash-generating capacity, and belief that IQVIA's stock is undervalued. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
<small>Source: CNBC</small>
